Arcus Biosciences, Inc. (RCUS) |
|
20.16 -0.1 (-0.49%)
|
05-31 12:18 |
|
Open: |
20.17 |
Pre. Close: |
20.26 |
|
High:
|
20.91 |
Low:
|
19.61 |
|
Volume:
|
354,048 |
Market Cap:
|
1,474(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 11:49:24 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 26.29 One year: 30.7 |
| Support: |
Support1: 19.04 Support2: 16.9 |
| Resistance: |
Resistance1: 22.5 Resistance2: 26.29 |
| Pivot: |
18.84  |
| Moving Average: |
MA(5): 19.57 MA(20): 18.89
MA(100): 18.87  MA(250): 23.33 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 69.1 %D(3): 56.1 |
| RSI: |
RSI(14): 55.6 |
| 52-week: |
High: 36.13 Low: 15.69 |
| Average Vol(K): |
3-Month: 1,013 (K) 10-Days: 1,205 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RCUS ] has closed below upper band by 24.3%. Bollinger Bands are 16.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
22.4 - 22.53 |
22.53 - 22.63 |
|
Low:
|
19.88 - 20.05 |
20.05 - 20.18 |
|
Close:
|
20.02 - 20.26 |
20.26 - 20.46 |
|
Company Description |
|
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California. |
Headline News |
Tue, 30 May 2023
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual ... - Business Wire
Tue, 30 May 2023
Principal Financial Group Inc. Cuts Position in Arcus Biosciences ... - MarketBeat
Sat, 27 May 2023
Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Fri, 26 May 2023
Elevation, Arcus top healthcare gainers; Tilray, Monogram among ... - Seeking Alpha
Fri, 26 May 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Fri, 26 May 2023
Arcus Biosciences Inc (RCUS) has risen 21.37% Friday In Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
73 (M) |
| Shares Float |
49 (M) |
|
% Held by Insiders
|
28.6 (%) |
|
% Held by Institutions
|
75.6 (%) |
|
Shares Short
|
7,810 (K) |
|
Shares Short P.Month
|
7,680 (K) |
Stock Financials |
|
EPS
|
-3.78 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.21 |
|
Profit Margin (%)
|
-234.5 |
|
Operating Margin (%)
|
-251.3 |
|
Return on Assets (ttm)
|
-13.4 |
|
Return on Equity (ttm)
|
-40 |
|
Qtrly Rev. Growth
|
38.9 |
|
Gross Profit (p.s.)
|
-2.41 |
|
Sales Per Share
|
1.62 |
|
EBITDA (p.s.)
|
-4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-314 (M) |
|
Levered Free Cash Flow
|
-119 (M) |
Stock Valuations |
|
PE Ratio
|
-5.31 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.44 |
|
Price to Sales
|
12.31 |
|
Price to Cash Flow
|
-4.67 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
